Reports Q3 revenue $53.78M, consensus $52.28M. “Getting to positive adjusted EBITDA ahead of the fourth quarter was an important goal for our company,” said Peter Caldini, Chief Executive Officer. “We now turn our focus towards reaching cash flow positive next year. In the US, we were up 16% sequentially when markets can be down 20%-30% because of seasonality – making our results even more impressive. The fourth quarter is the strongest quarter for breast augmentation, and we are already seeing considerable acceleration in our US and OUS businesses. We expect to finish 2025 at an approximate 20% share of the US breast augmentation market and to meaningfully exceed our previous guidance of $40 million in US Motiva sales. These results suggest another strong year of growth for us in 2026. Perhaps most exciting, we are watching our minimally invasive platform change the market, demonstrating our potential to drive category growth and improve the economics for the surgeons.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs’ Adaptive Study on Gluteal Augmentation: Key Insights for Investors
- Promising Growth Potential for Establishment Labs Holdings: Buy Rating on Mia Femtech Platform Success
- Establishment Labs publishes Mia Femtech data in Aesthetic Surgery Journal
- Needham medtech & diagnostics analysts hold analyst/industry conference call
- Establishment Labs price target raised to $43 from $40 at Citi